{
 "context": "The following article called 'Swiss Stocks Are Little Changed Near Five-Year High' was published on 2013-03-15. The body of the article is as follows:\n    \nSwiss stocks  were little changed\nnear a five-year high before U.S. reports that may show\nindustrial production and  consumer confidence  increased.  Novartis AG (NOVN)  climbed as JPMorgan Chase & Co. upgraded the\ndrugmaker and the U.S. Food & Drug Administration designated an\nexperimental  lung cancer  treatment as a Breakthrough Therapy.\n Dufry AG (DUFN)  rose 1.1 percent after profit increased.  Lindt &\nSpruengli AG (LISN)  fell after the world\u2019s largest maker of premium\nchocolate reported earnings that missed analyst estimates.  The  Swiss Market Index (SMI)  was unchanged at 7,842.85 as of\n11:40 a.m. in Zurich, bringing the gauge\u2019s weekly advance to 1.3\npercent. The broader Swiss Performance Index added less than 0.1\npercent today.  The number of shares changing hands in companies on the SMI\nwas more than double the average of the past 30 days as options\nexpired, data compiled by Bloomberg showed.  Stocks climbed around the world yesterday as an unexpected\ndecline in U.S. jobless claims sent the benchmark Standard &\nPoor\u2019s 500 Index within two points of its October 2007 record.  A Federal Reserve report at 9:15 a.m. in  Washington  may\nshow U.S. industrial production climbed 0.4 percent in February\nafter a 0.1 percent drop the previous month, according to a\nBloomberg survey of 83 economists. The Thomson\nReuters/University of Michigan preliminary index of  consumer\nsentiment  for March climbed to 78 from 77.6 last month, a\nseparate survey predicted.  Novartis Gains  Novartis rose 0.4 percent to 65.70 francs after JPMorgan\nraised its recommendation to overweight, the equivalent of a buy\nrating, from neutral. Separately, the FDA gave Novartis\u2019s LDK378\ncompound a Breakthrough Therapy designation for the treatment of\npatients with lung cancer.  In addition, two people with knowledge of the matter said\nHikma Pharmaceuticals Plc\u2019s injectable-drug business has drawn\ninterest from companies including Novartis. Spokesmen for\nNovartis and Hikma declined to comment.  Dufry advanced 0.8 percent to 123.70 francs, snapping seven\ndays of losses. The operator of duty-free shops said 2012\nearnings before interest, taxes, depreciation and amortization\nincreased 28 percent to 474 million francs.  Lindt dropped 1.1 percent to 40,560 francs. The company\nreported a 12 percent increase in 2012 net income to 271.9\nmillion francs ($287 million), missing the 277 million-franc\naverage estimate of four analysts surveyed by Bloomberg.  Daetwyler Holding AG (DAE) , a provider of engineering and\nelectronics components, climbed 2.8 percent to 102.70 francs.\nThe company reported a 33 percent gain in full-year net income\nto 127.5 million francs.  To contact the reporter on this story:\nSarah Jones in London at \n sjones35@bloomberg.net   To contact the editor responsible for this story:\nAndrew Rummer at \n arummer@bloomberg.net\n\n    The day before the article was published, the stock price of JP Morgan Chase & Co. was 39.90606689453125 and the day after the article was published, the stock price of JP Morgan Chase & Co. was ",
 "expected": "38.740177154541016",
 "date": "2013-03-15",
 "ticker": "JPM",
 "company": "JP Morgan Chase & Co.",
 "url": "http://www.bloomberg.com/news/2013-03-15/swiss-stocks-are-little-changed-near-five-year-high.html"
}